Gemcitabine and taxanes in metastatic breast cancer: A systematic review

Vinay Gudena, Alberto J. Montero, Stefan Glück

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to rates in stage IV lung (3%) and pancreatic cancers (1%). Despite these advances, MBC remains an incurable disease, often associated with many symptoms and a decreased quality of life (QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-free survival and overall survival rates, while at the same time improving QoL by palliation of symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. Once chemotherapy is indicated, a number of drugs and regimens are available but only a few offer both palliation of symptoms (responses to therapy) and overall survival benefit. The addition of novel biologic compounds to chemotherapy has been shown in phase III trials to improve all the above mentioned clinical outcomes in MBC. This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC.

Original languageEnglish
Pages (from-to)1157-1164
Number of pages8
JournalTherapeutics and Clinical Risk Management
Volume4
Issue number6
StatePublished - Dec 1 2008
Externally publishedYes

Fingerprint

gemcitabine
Taxoids
Chemotherapy
cancer
Breast Neoplasms
Drug Therapy
Toxicity
Survival Rate
Quality of Life
quality of life
Therapeutics
Life Expectancy
Pancreatic Neoplasms
Pharmaceutical Preparations
Disease-Free Survival
life expectancy
Lung Neoplasms

Keywords

  • Gemcitabine
  • Metastatic breast cancer
  • Taxanes

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Safety Research
  • Chemical Health and Safety

Cite this

Gemcitabine and taxanes in metastatic breast cancer : A systematic review. / Gudena, Vinay; Montero, Alberto J.; Glück, Stefan.

In: Therapeutics and Clinical Risk Management, Vol. 4, No. 6, 01.12.2008, p. 1157-1164.

Research output: Contribution to journalArticle

Gudena, V, Montero, AJ & Glück, S 2008, 'Gemcitabine and taxanes in metastatic breast cancer: A systematic review', Therapeutics and Clinical Risk Management, vol. 4, no. 6, pp. 1157-1164.
Gudena, Vinay ; Montero, Alberto J. ; Glück, Stefan. / Gemcitabine and taxanes in metastatic breast cancer : A systematic review. In: Therapeutics and Clinical Risk Management. 2008 ; Vol. 4, No. 6. pp. 1157-1164.
@article{b221978c18a542fe89749f0115bc81f0,
title = "Gemcitabine and taxanes in metastatic breast cancer: A systematic review",
abstract = "Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27{\%} which compares favorably to rates in stage IV lung (3{\%}) and pancreatic cancers (1{\%}). Despite these advances, MBC remains an incurable disease, often associated with many symptoms and a decreased quality of life (QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-free survival and overall survival rates, while at the same time improving QoL by palliation of symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. Once chemotherapy is indicated, a number of drugs and regimens are available but only a few offer both palliation of symptoms (responses to therapy) and overall survival benefit. The addition of novel biologic compounds to chemotherapy has been shown in phase III trials to improve all the above mentioned clinical outcomes in MBC. This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC.",
keywords = "Gemcitabine, Metastatic breast cancer, Taxanes",
author = "Vinay Gudena and Montero, {Alberto J.} and Stefan Gl{\"u}ck",
year = "2008",
month = "12",
day = "1",
language = "English",
volume = "4",
pages = "1157--1164",
journal = "Therapeutics and Clinical Risk Management",
issn = "1176-6336",
publisher = "Dove Medical Press Ltd.",
number = "6",

}

TY - JOUR

T1 - Gemcitabine and taxanes in metastatic breast cancer

T2 - A systematic review

AU - Gudena, Vinay

AU - Montero, Alberto J.

AU - Glück, Stefan

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to rates in stage IV lung (3%) and pancreatic cancers (1%). Despite these advances, MBC remains an incurable disease, often associated with many symptoms and a decreased quality of life (QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-free survival and overall survival rates, while at the same time improving QoL by palliation of symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. Once chemotherapy is indicated, a number of drugs and regimens are available but only a few offer both palliation of symptoms (responses to therapy) and overall survival benefit. The addition of novel biologic compounds to chemotherapy has been shown in phase III trials to improve all the above mentioned clinical outcomes in MBC. This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC.

AB - Incremental advances over the last two decades in the treatment of stage IV metastatic breast cancer (MBC) have resulted in significantly prolonging the average life expectancy. In 2008, the estimated 5-year relative survival rate for MBC is 27% which compares favorably to rates in stage IV lung (3%) and pancreatic cancers (1%). Despite these advances, MBC remains an incurable disease, often associated with many symptoms and a decreased quality of life (QoL). Therefore, therapy goals in the treatment of MBC include prolonging both progression-free survival and overall survival rates, while at the same time improving QoL by palliation of symptoms. Therefore, systemic chemotherapy ideally should not induce unnecessary toxicities. Once chemotherapy is indicated, a number of drugs and regimens are available but only a few offer both palliation of symptoms (responses to therapy) and overall survival benefit. The addition of novel biologic compounds to chemotherapy has been shown in phase III trials to improve all the above mentioned clinical outcomes in MBC. This review will discuss data supporting the use of gemcitabine/taxane combinations in the treatment of MBC.

KW - Gemcitabine

KW - Metastatic breast cancer

KW - Taxanes

UR - http://www.scopus.com/inward/record.url?scp=61549099055&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=61549099055&partnerID=8YFLogxK

M3 - Article

C2 - 19337423

AN - SCOPUS:61549099055

VL - 4

SP - 1157

EP - 1164

JO - Therapeutics and Clinical Risk Management

JF - Therapeutics and Clinical Risk Management

SN - 1176-6336

IS - 6

ER -